IL297596A - Modulators of akt3 and methods of using them - Google Patents

Modulators of akt3 and methods of using them

Info

Publication number
IL297596A
IL297596A IL297596A IL29759622A IL297596A IL 297596 A IL297596 A IL 297596A IL 297596 A IL297596 A IL 297596A IL 29759622 A IL29759622 A IL 29759622A IL 297596 A IL297596 A IL 297596A
Authority
IL
Israel
Prior art keywords
alkyl
cycloalkyl
akt3
aryl
disease
Prior art date
Application number
IL297596A
Other languages
English (en)
Hebrew (he)
Original Assignee
Georgiamune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiamune Llc filed Critical Georgiamune Llc
Publication of IL297596A publication Critical patent/IL297596A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplitude Modulation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL297596A 2020-05-08 2021-05-07 Modulators of akt3 and methods of using them IL297596A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021797P 2020-05-08 2020-05-08
PCT/US2021/031372 WO2021226510A2 (en) 2020-05-08 2021-05-07 Akt3 modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
IL297596A true IL297596A (en) 2022-12-01

Family

ID=78468492

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297596A IL297596A (en) 2020-05-08 2021-05-07 Modulators of akt3 and methods of using them

Country Status (12)

Country Link
US (1) US20230181563A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146196A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023525758A (cg-RX-API-DMAC7.html)
KR (1) KR20230019109A (cg-RX-API-DMAC7.html)
CN (1) CN115956078A (cg-RX-API-DMAC7.html)
AU (1) AU2021269065A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022327A2 (cg-RX-API-DMAC7.html)
CA (1) CA3182675A1 (cg-RX-API-DMAC7.html)
IL (1) IL297596A (cg-RX-API-DMAC7.html)
MX (1) MX2022014019A (cg-RX-API-DMAC7.html)
PH (1) PH12022553026A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021226510A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021212111A1 (en) * 2020-04-17 2021-10-21 Augusta University Research Institute, Inc. Compositions and methods for treating leukemia
US20230295114A1 (en) * 2020-05-08 2023-09-21 Georgiamune Llc Akt3 modulators
CN115867562A (zh) * 2020-05-08 2023-03-28 乔治穆内有限责任公司 Akt3调节剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001256A (es) * 2000-08-11 2004-12-06 Vertex Pharma Inhibidores de p38.
DE602004026047D1 (de) * 2003-04-24 2010-04-29 Merck Sharp & Dohme Hemmer der akt aktivität
EP2078008A2 (en) * 2006-10-12 2009-07-15 SuperGen, Inc. Quinoline derivatives for modulating dna methylation
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7939546B2 (en) * 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
US9707278B2 (en) * 2014-04-17 2017-07-18 Augusta University Research Institute, Inc. Methods of modulating immune responses by modifying Akt3 bioactivity
US10292978B2 (en) * 2016-01-15 2019-05-21 Augusta University Research Institute, Inc. Specific Akt3 inhibitor and uses thereof
US10342868B2 (en) * 2016-01-15 2019-07-09 Augusta University Research Institute, Inc. Methods and compositions for inhibiting Akt3
US20210208778A1 (en) * 2017-06-29 2021-07-08 Hewlett-Packard Development Company, L.P. Contiguous planar display operable to have area functioning as primary display and area functioning as secondary display
EP3678666B1 (en) * 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof

Also Published As

Publication number Publication date
US20230181563A1 (en) 2023-06-15
PH12022553026A1 (en) 2024-05-13
EP4146196A2 (en) 2023-03-15
AU2021269065A1 (en) 2022-12-15
KR20230019109A (ko) 2023-02-07
MX2022014019A (es) 2023-02-16
WO2021226510A9 (en) 2022-01-13
CA3182675A1 (en) 2021-11-11
WO2021226510A3 (en) 2021-12-16
JP2023525758A (ja) 2023-06-19
WO2021226510A2 (en) 2021-11-11
BR112022022327A2 (pt) 2023-01-03
EP4146196A4 (en) 2024-06-26
CN115956078A (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
US12616690B2 (en) Specific AKT3 activator and uses thereof
Fang et al. In situ polymerization of zwitterions on therapeutic proteins to enable their effective oral delivery
CN105164143B (zh) 用于将分子引入到乳糜微粒中的胆固醇体囊泡
WO2018057825A1 (en) Antigen-specific immune modulation
JP2004535402A (ja) 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
IL292567A (en) Peptide conjugated particles
AU2021269065A1 (en) Akt3 modulators and methods of use thereof
US20220280557A1 (en) Metabolic Reprogramming of Immune Cells for the Treatment or Prevention of Diseases and Disorders
US20220016256A1 (en) Methods, device and reagents to treat allergy and autoimmune disease
CN109134664B (zh) 一种经修饰的生长分化因子及其制备方法和应用
Wu et al. Biomimetic “Trojan Horse” fibers modulate innate immunity cascades for nerve regeneration
JP2024532810A (ja) 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
JP2003231698A (ja) 自己免疫性を改善せしめるうえで有用なｍｈｃコンジュゲート
Peake et al. Controlled release of C-type natriuretic peptide by microencapsulation dampens proinflammatory effects induced by IL-1β in cartilage explants
Zhang et al. Intranasal delivery of hydrophobic AC5216 loaded nanoemulsion into brain to alleviate chronic unpredictable stress-induced depressive-like behaviors
CN115552013A (zh) 修饰的微核小体核心蛋白及其在核酸递送中的用途
JP2019534300A (ja) プログラム細胞死リガンド１の腸管発現
Gu et al. Dual Pro‐Angiogenic and Pro‐Fibrotic MARCO+ Microglial Phenotype in Diabetic Retinopathy
JP7630540B2 (ja) 神経保護ペプチド
CA2750005C (fr) Polypeptides d'adressage specifique a des cellules-cibles d'otx2
HK40084846A (en) Akt3 modulators and methods of use thereof
US20200405763A1 (en) Irf-4 engineered t cells and uses thereof in treating cancer
Kakunuri a proliferation inducing ligand as a neuroregenerative treatment in multiple sclerosis
RU2815372C2 (ru) Специфический активатор akt3 и его применение
Xie Engineering T Cell Trafficking and Function for Enhanced Cancer Immunotherapy